Changes in body fat concentration, affecting people with HIV, is known as HIV-associated lipodystrophy. The exact causes of this condition is currently unknown, but research suggests that this disorder can occur either due to HIV infection or as a consequence of side effects associated with drugs used in HIV infection treatment, such as Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs), Protease Inhibitors (PIs), etc. The lipodystrophy condition is characterized by metabolic abnormalities, including insulin resistance, and dyslipidemia. The HIV-associated lipodystrophy groups together different clinical conditions, which are lipoatrophy and lipoaccumulation. Lipoatrophy is associated with subcutaneous fat loss, whereas lipoaccumulation is the increase in visceral fat. In certain cases, HIV-associated lipodystrophy may occur as a combination of these two conditions; thus, its treatment and prevalence measurement are difficult.

The global HIV-associated lipodystrophy market is witnessing unprecedented dynamics. Several research studies are directed toward finding out the link between the two mechanisms of lipodystrophy in such a way that a single mechanism will can occur for redistribution of fat. Improving healthcare infrastructure and increasing incidence rates of HIV/AIDS patients globally are expected to drive the growth of the global HIV-associated lipodystrophy market. However, lower adoption of therapeutic treatment and demand for constant nutritional supply from patients is anticipated to restrain the growth of the global HIV-associated lipodystrophy market.

The global HIV-associated lipodystrophy market has been segmented based on lipodystrophy type, therapeutic class, and distribution channels. On the basis of lipodystrophy type, the market has been classified into lipoatrophy and lipoaccumulation. In terms of therapeutic class, the market is divided into anabolism modulators, insulin resistance modulators, mitochondrial antioxidants (L-carnitine), and other miscellaneous metabolic agents. Anabolism modulators are further bifurcated into growth hormones and anabolic steroids. Insulin resistance modulators can be sub-segmented into metformins, thiazolidinediones, and others. Growth hormones are widely used for the treatment of HIV-associated lipodystrophy due to their efficacy. Based on distribution channels, the global HIV-associated lipodystrophy market is categorized into hospital pharmacy stores, retail pharmacy stores, and online pharmacies. Hospital pharmacy stores are expected to account for higher market share due to their ease of connectivity, and trend of utilization of newly advanced products among end-users including physicians and patients.

There is a lack of evidence-based strategies for the treatment of HIV-associated lipodystrophy. The treatment switch between the two lipodystrophy conditions, along with HIV drugs that possess lower mitochondrial toxicity, is an emerging trend in the global HIV-associated lipodystrophy market. There is a large patient pool in emerging countries, where lower drug affordability is a major challenge for market penetration of HIV-associated lipodystrophy therapeutics. Thus, the introduction of affordable drugs by local manufacturers serves as a major opportunity in the global HIV-associated lipodystrophy market. However, the other treatment options such as cosmetic surgeries also arrests the growth of the global HIV-associated lipodystrophy market.

On the basis of geography, the global HIV-associated lipodystrophy market has been divided into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is expected to grow at a high CAGR owing to factors like large patient pool, increasing demand for low cost drugs, rising awareness of the treatment options for HIV-associated lipodystrophy, and adoption of better healthcare facilities. North America is projected to dominate the global HIV-associated lipodystrophy market due to increasing adoption of new and technologically advanced products, high per capita health expenditure, and substantial investments in research and development for efficient treatment options.

Key players in the global HIV-associated lipodystrophy market are Novelion Therapeutics Inc., Theratechnologies Inc., Gilead Sciences Inc., GlaxoSmithKline plc (Viiv Healthcare Group of Companies), AbbVie Inc., Bristol-Myers Squibb Company, and AstraZeneca plc, among others.

This intelligence report by TMR is the outcome of intense study and rigorous assessment of various dynamics shaping the growth of the market. TMR nurtures a close-knit team of analysts, strategists, and industry experts who offer clients tools, methodologies, and frameworks to make smarter decisions. Our objective, insights, and actionable analytics provide CXOs and executives to advance their mission-critical priorities with confidence.

The scrutiny of the various forces impacting the dynamics of the market, and key and associated industries, guides enterprises in understanding various consumer propositions. Our clients leverage these insights and perspectives to enhance customer experience in the fast-paced business environment.

All our insights and perspectives are broadly based on 4 Pillars or Stages: ASBC-S, which offer an elaborate and customizable framework for the success of an organization. The essence and the roles of these in organizational successes are highlighted below:

  • Agenda for CXOs: TMR, through the study, sets the tone for agendas that are pertinent to CEOs, CFOs, CIOs, and other CXO executives of businesses operating in the market. The perspectives help our clients to bridge the gap between agenda and action plan. TMR strives to offer guidance to CXOs to undertake mission-critical activities empowered by various business analysis tools, and boost the performance of the organizations. The perspectives guide you to decide on your own marketing mix that align well with the policies, visions, and mission.
  • Strategic Frameworks: The study offers how organizations are setting both short-term and long-term strategic plans. Our team of experts collaborate and communicate with you to understand these to make your organizations sustainable and resilient during tough times. The insights help them decide sustainable competitive advantage for each business units.
  • Benchmarking for Deciding Target Markets and Brand Positioning: The assessments in the study provides a scrutiny of marketing channels and marketing mix. Our various teams work synergistically with you to help identify your actual and potential direct, indirect, and budget competition areas. Additionally, the study helps you decide most effective budgets for various processes and promotional activities. Furthermore, the study guides you to set benchmarks for integrating people and processes with the 4Ps of marketing. Eventually, this will empower you to find out unique propositioning strategies and niches.
  • Business Composability for Sustainability (C-S): Constant strategy planning for sustainability characterizing our C-S framework in the report has become more relevant than before in the face of disruptions caused by pandemics, recessions, boom and bust cycles, and changing geopolitical scenario. The TMR study offers a high level of customization to help you achieve business composability. Composable enterprises are increasingly gaining the attention of CXOs in order to help them combat market volatility. Our analysts and industry experts help you wade through such uncertainties and guide you to become a smart sustainable business in entirety.

The study presents scrutiny of region-specific consumer and technology trends, including the most recent industry dynamics. These broadly cover but not limited to

  • North America, South America, and the Americas
  • Asia Pacific and Japan
  • Europe
  • Latin America
  • Middle East and Africa

The study offers data-driven insights and guidance of several aspects. Some of the more notable questions are:

  • What are the major recent trends that can influence the product life cycle and the RoI?
  • Which regulatory trends shape corporate-level, business-level, and functional-level strategies?
  • Which micromarketing initiatives of leading players will bring in investments?
  • What can be the best framework and tools for PESTLE analysis?
  • Which regions will witness rise in new opportunities?
  • Which are the game-changing technologies being used to capture new revenue streams in the near future?
  • Which operational and tactical frameworks are being adopted by various players in gaining customer loyalty?
  • What is the current and expected intensity of competition the market in the near future?

Disclaimer: This market research study is an ongoing effort and extreme care has been taken to maintain the highest levels of accuracy at all stages. However, in the light of the rapidly evolving business dynamics, some region-specific or other segment-specific changes may take time to be part of the study.

Enquiry Before Buying

TMR offers Enquiry Before Buying that help clients to get information on their business scenario required where syndicated solutions are not enough.

Enquiry Before Buying

HIV-associated Lipodystrophy Market